Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Predicting visual acuity deterioration and radiation-induced toxicities after brachytherapy for choroidal melanomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association of Choroidal Effusion and Infusion of Daratumumab

    Publikation: Bidrag til tidsskriftLetterForskning

  3. The genetic evolution of metastatic uveal melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Bruch's membrane allows unhindered passage of up to 2 μm latex beads in an in vivo porcine model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Inconsistent distortion in ultra-widefield fundus image

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  • Kalijn Fredrike Bol
  • Eva Ellebaek
  • Lise Hoejberg
  • Mette Marie Bagger
  • Mathilde Skaarup Larsen
  • Tobias Wirenfeldt Klausen
  • Ulrich Heide Køhler
  • Henrik Schmidt
  • Lars Bastholt
  • Jens Folke Kiilgaard
  • Marco Donia
  • Inge Marie Svane
Vis graf over relationer

Uveal melanoma (UM) is the most common intraocular malignancy in adults and shows a high rate of metastatic spread. As randomized clinical trials with immune checkpoint inhibitors (ICI) have not been performed in patients with metastatic UM, we analyzed the real-world outcomes in a nationwide population-based study. Clinical data of patients with UM were extracted from the Danish Metastatic Melanoma database, a nationwide database containing unselected records of patients diagnosed with metastatic melanoma in Denmark. Survival before (pre-ICI, n = 32) and after (post-ICI, n = 94) the approval of first-line treatment with ICI was analyzed. A partial response to first-line treatment was observed in 7% of patients treated with anti-programmed cell death protein (PD)-1 monotherapy and in 21% with combined anti-cytotoxic T lymphocyte antigen (CTLA)-4 plus anti-PD-1 therapy. Median progression-free survival was 2.5 months for patients treated in the pre-ICI era compared to 3.5 months in the post-ICI era (hazard ratio (HR) 0.43; 95% confidence interval (CI) 0.28-0.67; p < 0.001). The estimated one-year overall survival rate increased from 25.0% to 41.9% and the median overall survival improved from 7.8 months to 10.0 months, respectively (HR 0.52; 95% CI 0.34-0.79; p = 0.003). Thus, the introduction of ICI as first-line treatment appears to have significantly improved the real-world survival of patients with metastatic UM, despite relatively low response rates compared to cutaneous melanoma. With the lack of therapies proven effective in randomized trials, these data support the current treatment with ICI in patients with metastatic UM.

Udgave nummer10
StatusUdgivet - 3 okt. 2019

ID: 58521057